Upstate NY Chapter Home News Vaccinex, Inc. Announces Completion of Enrollment for Its "SIGNAL) Huntington's Disease Trial
Vaccinex, Inc. Announces Completion of Enrollment for Its "SIGNAL) Huntington's Disease Trial
ROCHESTER, N.Y., Jan. 16, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) announced today that it has completed subject enrollment for the SIGNAL trial. SIGNAL is a Phase 2, multi-center, randomized, double-blind, placebo controlled study in subjects with early manifest and late prodromal Huntington’s disease (HD) to assess the safety, tolerability, pharmacokinetics, and efficacy of VX15/2503 (pepinemab).
